Cited by 169Bone health and osteoporosis researchBone health and treatmentsMenopause: Health Impacts and Treatments

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Denosumab: A Review in Postmenopausal Osteoporosis

Deeks, Emma D.·2018·Drugs & Aging

Open this paper in CoChat — free account

Abstract

Denosumab (Prolia ® ; Pralia ® ) is a human monoclonal antibody targeting the key bone resorption mediator RANKL. The drug is administered via subcutaneous injection once every 6 months and is approved for various indications, including the treatment of postmenopausal (PM) women with osteoporosis at increased/high risk of fracture or failure/intolerance of other osteoporosis therapies (indications featured in this review). Denosumab showed benefit in several phase 3 or 4 studies in PM women with osteoporosis or low bone mineral density (BMD), including the pivotal 3-year double-blind FREEDOM trial and its 7-year open-label extension. Denosumab reduced the risk of vertebral, nonvertebral and hip fractures and increased BMD across skeletal sites versus placebo in FREEDOM, with these benefits maintained over up to 10 years' therapy in the extension. The drug was also more effective in improving BMD than bisphosphonates, including in women switched from a bisphosphonate regimen, in 1-year trials; however, whether these differences translate into differences in anti-fracture efficacy is unclear. Denosumab was generally well tolerated over up to 10 years' treatment, although an increased risk of multiple vertebral fractures was observed after discontinuation of the drug. Thus, denosumab is a key treatment option for PM women with osteoporosis who have an increased/high risk of fracture or failure/intolerance of other osteoporosis therapies, although the potential for multiple verte…

Integrity signals

Registry

Crossref · 10.1007/s40266-018-0525-7

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Postmenopausal Osteoporosis
Black, D. M., & Rosen, C. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmcp1513724 · Cited by 1,790
American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016--Executive Summary
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.esgl · Cited by 1,140
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
Bone, H. G., Wagman, R. B., Brandi, M. L., Brown, J. P., Chapurlat, R., Cummings, S. R., Czerwiński, E., Fahrleitner-Pammer, A., Kendler, D. L., Lippuner, K., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30138-9 · Cited by 996
Postmenopausal osteoporosis
Eastell, R., O’Neill, T. W., Hofbauer, L. C., Langdahl, B. L., Reid, I. R., Gold, D. T., & Cummings, S. R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.69 · Cited by 877
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
Cummings, S. R., Ferrari, S., Eastell, R., Gilchrist, N. L., Jensen, J. B., McClung, M. R., Roux, C., Törring, O., Valter, I., Wang, A. T., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3337 · Cited by 753
Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Miller, P. D., Yang, Y., Grazette, L. P., Martín, J. S., & Gallagher, J. C. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1502 · Cited by 634
Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial
Brown, J. P., Prince, R. L., Deal, C. L., Recker, R. R., Kiel, D. P., de Gregorio, L. H., Hadji, P., Hofbauer, L. C., Álvaro‐Gracia, J. M., Wang, H., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0809010 · Cited by 616
Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS
Tsourdi, E. A., Langdahl, B. L., Cohen-Solal, M. E., Aubry‐Rozier, B., Eriksen, E. F., Guañabens, N., Obermayer-Pietsch, B. M., Ralston, S. H., Eastell, R., & Zillikens, M. C. (2017) · Bone · doi:10.1016/j.bone.2017.08.003 · Cited by 508
American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.gl · Cited by 491

Show all 55 references

Research works printed but not linked: 2

Zhang Y, Zhang L, Li S, et al. Effect of denosumab, a fully human monoclonal antibody to RANKL, on bone mineral density and fractures: a meta-analysis. Int J Clin Exp Med. 2017;10(4):5931–40.
Insinga RP. Administration costs of denosumab and zoledronic acid for postmenopausal osteoporosis. Am J Pharm Benefits. 2016;8(3):e42–7.

Sorted by citations

Items 101–169 of 169

Chronic pancreatitis-associated metabolic bone diseases: epidemiology, mechanisms, and clinical advances
Wang, T., Xiong, K., He, Y., Feng, B., Guo, L., Gu, J., Zhang, M., Wang, H., & Wu, X. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00113.2024 · Cited by 7
Orally administrable peptides derived from egg yolk promote skeletal repair and ameliorate degenerative skeletal disorders in mouse models
Kitaura, Y., Nakamura, U., Awada, C., Yamaguchi, M., Kim, M., Ikeda, Y., Matsuo, Y., Moriishi, T., Sawase, T., Chung, U., et al. (2022) · Regenerative Therapy · doi:10.1016/j.reth.2022.11.002 · Cited by 7
Risk factors of medication-related osteonecrosis of the jaw: A clinical investigation
Komatsu, Y., Kawai, T., Hirano, T., Hoshi, I., Yamaya, G., Ogawa, A., Chiba, T., & Yamada, H. (2024) · Journal of Stomatology Oral and Maxillofacial Surgery · doi:10.1016/j.jormas.2024.101791 · Cited by 6
Periplaneta Americana extract inhibits osteoclastic differentiation in vitro
Zhao, B., Zhang, Y., Xu, J. C., Li, Y., Yuan, Q., & Zhou, C. (2022) · Cell Proliferation · doi:10.1111/cpr.13341 · Cited by 6
A randomized, double blind, parallel design, repeat dose, 2-arm, multicenter study comparing the efficacy, safety, immunogenicity, and pharmacokinetic profiles of a denosumab biosimilar, AVT03, in postmenopausal women with osteoporosis
Lortkipanidze, M., de Villiers, T., Kania, G., Bullo, F., Jaśkiewicz, Ł., Stamatakos, S., Rai, M., Haliduola, H. N., Otto, H., Sattar, A., et al. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2538609 · Cited by 5
Ergothioneine alleviates osteoporosis via the ROS-MAPK signaling Axis
Guo, Z., Huang, Y., Wang, X., Han, Y., Li, A., Qu, Y., Chen, L., Du, M., Zhang, Y., & Xu, Y. (2025) · Bone · doi:10.1016/j.bone.2025.117496 · Cited by 5
Isorhamnetin ameliorates ovariectomy-induced osteoporosis in female rats by regulating the receptor activator of nuclear factor kappa B ligand, osteoprotegerin, bone morphogenetic protein 2 and runt-related transcription factor 2 signaling pathway
Haibin, J. I. A. O., & ZHENG, K. (2025) · Journal of Veterinary Medical Science · doi:10.1292/jvms.25-0006 · Cited by 5
Risks vs. benefits of switching therapy in patients with postmenopausal osteoporosis
Ishizu, H., Arita, K., Terkawi, M. A., Shimizu, T., & Iwasaki, N. (2021) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2021.1956902 · Cited by 5
Sulfated galactofucan from Sargassum fusiforme protects against postmenopausal osteoporosis by regulating bone remodeling
Yizhong, B., Chen, F., Jin, W., Dai, J., Mao, G., & Song, B.-S. (2024) · Communications Biology · doi:10.1038/s42003-024-07097-2 · Cited by 5
Denosumab-induced alopecia areata with lichenoid eruption
Dourra, M., Mussad, S., Qiblawi, S. H., & Singer, R. (2021) · JAAD Case Reports · doi:10.1016/j.jdcr.2021.09.003 · Cited by 5
Postmenopausal Osteoporosis: A Mini Review
Shuai, Y., Zhang, Z., Guo, T., Yang, R., Lei, J., & Liu, W. (2019) · EMJ Rheumatology · doi:10.33590/emjrheumatol/10311765 · Cited by 5
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study of Jianyao Migu Granules in the Treatment of Osteopenic Low Back Pain
Qin, Z., Xu, K., Mo, W., Ye, J., & Xu, J. (2022) · Journal of Pain Research · doi:10.2147/jpr.s377082 · Cited by 4
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese subjects
Wang, S., Yang, X., Huang, J. M., Yang, S., Wu, Q., Chen, H., Wu, S., Dou, C., Yang, G., & Xiang, Y. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2120389 · Cited by 4
Comparative effectiveness of bisphosphonate treatments for the prevention of re-fracture in glucocorticoid-induced osteoporosis: protocol for a systematic review and meta-analysis
Chu, H., Jang, B.-H., Kim, G., Bae, S., Lee, H., Nam, S., & Ahn, J. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-062537 · Cited by 4
Vaccine of RANKL mutant conjugated with KLH effectively stabilizing bone metabolism and preventing trabecular microstructural degeneration in osteoporotic rats
Zhang, S., Wang, M., Li, J., Li, Y., Zhou, J., Tian, Z., Liu, C., & Yao, Q. (2020) · Journal of Orthopaedic Research® · doi:10.1002/jor.24980 · Cited by 4
Patterns of adjuvant bone modifying agent use in patients with early-stage breast cancer in the United States
Odzer, N. B., Chehayeb, R. J., Schellhorn, S. E., Lustberg, M. B., Gross, C. P., Lee, D. K., & Foldi, J. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-02062-1 · Cited by 3
Alternative Splicing: A Critical Regulator in Human Bone Biology and Tumor Progression
Cao, L., Hu, Y., Jia, K., Ruiz-Cardozo, M. A., Chen, E., Yang, J., Shao, Z., Tine, B. A. V., & Wu, W. (2025) · Research · doi:10.34133/research.0977 · Cited by 4
Hyperparathyroidism Following Denosumab and Zoledronate Therapy in a Secondary Care Setting
Kotecha, J., Fardeen, K. M., & Mirzazadeh, M. (2022) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001894 · Cited by 3
Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational study
Buch‐Larsen, K., Jørgensen, N. R., Jensen, L. T., Andersson, M., & Schwarz, P. (2021) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2021.1929447 · Cited by 3
Targeted Dual Microdroplets for Modulating Osteoclast Differentiation and Function: A Novel Therapeutic Approach to Combat Osteoporosis
Shi, M., Jin, F., Chen, P., Zhu, B., Sun, L., Ma, Y., Zhang, Y., & Wang, X. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c21489 · Cited by 4
Melatonin Mediates Osteoblast Proliferation Through the STIM1/ORAI1 Pathway
Cao, L., Yang, K., Yuan, W., Zhou, S., Zhao, R., & Qiu, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.851663 · Cited by 7
Retracted
Effects of anti-osteoporotic drugs in patients with chronic kidney disease: a systemic review and network meta-analysis of bone mineral density, clinical fracture rate and renal function
Wung, C.-H., Liu, H., Tsai, T., & Chen, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1569744 · Cited by 2
NFATc1-targeted siRNA microdroplets prevent radiation-induced osteoporosis by coordinating bone-immune crosstalk
Zhang, Y., Zhang, L., Yang, X., Liu, X., Liu, R., Huang, W., Wang, Y. H., Ma, Y., Xiao, Y., Sima, J., et al. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.08.057 · Cited by 2
Effectiveness of Sequential Treatment with Zoledronic Acid Following Discontinuation of Denosumab in Osteoporosis: A Narrative Review
Ouyang, H. W., Yang, F., Wei, W., & Wang, W. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s549062 · Cited by 2
Real-world persistence and compliance of denosumab versus alendronate among postmenopausal women with osteoporosis in Asia–Pacific
Lau, T. C., Chang, D., Chen, C., Huang, S., Lau, E. M. C., Law, S. W., Lee, Y., Tolman, C., Canals, L., Yeo, S., et al. (2025) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-025-01663-2 · Cited by 4
Effectiveness of treatments to prevent femoral periprosthetic bone loss following total hip arthroplasty: a network meta-analysis
Zhao, Z., Ling, T., Ye, S., Luo, W., Ma, J., & Ma, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1566890 · Cited by 2
The anti-osteoporotic effect of puerarin on the femoral bone in rat models of osteoporosis: a systematic review and meta-analysis
Yang, Z., Tang, R., Ma, Y., Luo, W., & Hu, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1712682 · Cited by 2
Pregnancy‐ and lactation‐associated osteoporosis: A position statement of the IAPM , IOF , ECTS , ESCEO , IMS , and EMAS
Hadji, P., Athanasiadis, A., Brandi, M., Chakhtoura, M., Chandran, M., Chervenak, F. A., Grunebaum, A. N., Lambrinoudaki, I. V., Lems, W. F., Mamopoulos, A. M., et al. (2026) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.71203 · Cited by 2
Biopolymers/Ceramic-Based Nanocomposite Scaffolds for Drug Delivery in Bone Tissue Engineering
Lavanya, K., Swetha, S. V., & Selvamurugan, N. (2021) · Advances in material research and technology · doi:10.1007/978-3-030-70266-3_11 · Cited by 2
The Trend in the Sales of Menopausal Hormone and Other Osteoporosis Medications in South Korea from 2016 to 2019
Lee, E. S., Kwon, S., & Park, H. M. (2021) · Journal of Bone Metabolism · doi:10.11005/jbm.2021.28.3.201 · Cited by 2
Effect of Locally Administered Denosumab on Bone Graft Healing in Rabbit Critical-Size Calvarial Defects.
Özer, T., Başlarlı, Ö., Aktaş, A., Barış, E., & Ocak, M. (2022) · Indian Journal of Orthopaedics · doi:10.1007/s43465-022-00673-w · Cited by 2
Engineered Plant Virus Complexes with a RANK Motif Modulator and Bone Targeting for Osteoporosis Treatment
Li, Y., Cao, S., Li, Q., Li, H., Yu, L., Shao, B., Yuan, Q., Zou, S., & Zhou, C. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c19632 · Cited by 2
Immune-based Therapies—What the Emergency Physician Needs to Know
Dubbs, S. B., Falat, C., & Rosenblatt, L. (2021) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2021.08.011 · Cited by 2
Toxic hepatitis in metastatic breast cancer patient using ribociclib and denosumab
Bayram, D., Esen, S. A., Uçar, G., & Köş, F. T. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231174593 · Cited by 2
Modeling Effects of Electromagnetic Fields on Bone Density on Humans in Microgravity
Lutz, K., Trevino, T., & Adrian, C. (2022) · AIAA Accelerating Space Commerce, Exploration, and New Discovery Conference (ASCEND) · doi:10.2514/6.2022-4291 · Cited by 1
Trends of denosumab-related publications in web of science
Jiang, X., Xie, T., Feng, W., Qin, Z., Liao, S., Liu, Y., Lu, S.-L., He, M., & Wei, Q. (2023) · Medicine · doi:10.1097/md.0000000000032784 · Cited by 1
Evaluation of Denosumab treatment on healing of calvarial bone defect: Histological experimental trial
Soliman, S., Shabaan, A. A., Mohamed, S., & Aboulmagd, I. (2023) · Egyptian Dental Journal /Egyptian Dental Journal · doi:10.21608/edj.2023.191903.2445 · Cited by 1
Osteoporosis: The most common postmenopausal women disorder: A review
Naser, I. H., Al-Kareem, Z. A., Mahdi, H. S., Mosa, A. U., & Ouda, M. H. (2024) · Maaen Journal for Medical Sciences · doi:10.55810/2789-9136.1049 · Cited by 1
Comprehensive overview of antibody drug-related clinical studies in gynecology: insights from ClinicalTrials.gov
Zhou, X., Li, X., Lai, F., Chen, W., Zhou, C., Deng, Y., Wang, T., Xing, S., Diao, H., Tang, M., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1521587 · Cited by 1
Denosumab Regulates Titanium Particles‐Induced Macrophages Inflammation and Osteolysis by Targeting the ST18 / PARP1 Interaction
Chen, Z., Yang, F., Yu, Y., Chen, J., Ye, J., & Ding, Y. (2025) · Orthopaedic Surgery · doi:10.1111/os.70211 · Cited by 1
Characteristics of osteoclasts at different developmental stages and therapeutic strategies
Fan, Z., Shuai, F., Xie, Y., Lin, Y., Yao, Y., Han, X., & Yin, Y. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118703 · Cited by 1
Efficacy and safety of denosumab biosimilars in the treatment of postmenopausal osteoporosis: A systematic review of randomized clinical trials
Shakibaei, F., Malekshahi, S., Heidari, N., & Heidari, A. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02070-1 · Cited by 1
Osteoporosis: Diagnosis and Management
Rawung, R., & Bagy, R. G. (2021) · e-CliniC · doi:10.35790/ecl.v9i2.32967 · Cited by 2
Az osteoporosis antirezorptív kezelésének biológiai alapjai és az állcsontok antirezorptív kezelés okozta osteonecrosisa
Gera, I., & Szücs, N. (2024) · Fogorvosi Szemle · doi:10.33891/fsz.117.1.11-21 · Cited by 1
Bioflavonoid Tangeretin regulates RANK/RANKL/OPG Signaling Proteins via Stimulating Estrogenic Activity in Ovariectomized Rats
Tian, W., Zhang, W., Chen, L., Liao, J., & Yang, X. (2024) · Pharmacognosy Magazine · doi:10.1177/09731296241296201 · Cited by 1
Effects of bushen qianggu method for primary osteoporosis
Chen, G., Guan, Y., Ye, X., Chen, G., Du, J., Liu, W., Zhao, C., Yao, N., & Xu, X. (2020) · Medicine · doi:10.1097/md.0000000000020697 · Cited by 1
Menopausal osteoporosis in the practice of a gynecologist
Kuznetsova, I. V., & Chilova, R. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-12-320-331 · Cited by 1
Effectiveness of Denosumab in Postmenopausal Osteoporosis Treatment: A 1-yr Follow-up Single-center Study
Tezel, N., Cankurtaran, D., Ecerkale, Ö., & Akyüz, E. Ü. (2021) · Turkish Journal of Osteoporosis · doi:10.4274/tod.galenos.2020.83435 · Cited by 1
Osteoporosis in Transfusion Dependent Thalassemia
Hashemieh, M. (2019) · مجله دانشگاه علوم پزشکی اراک · doi:10.32598/jams.22.5.2
Old Bones
Morley, J. E. (2020) · The journal of nutrition health & aging · doi:10.1007/s12603-020-1355-y
The role of interdisciplinary cooperation in the prevention of medication-related osteonecrosis of the jaw (MRONJ)
Teślak, M., Chlebus, I., & Ordyniec-Kwaśnica, I. (2020) · European Journal of Translational and Clinical Medicine · doi:10.31373/ejtcm/120581
Evaluation of Patient Satisfaction, Back Pain, and Bone Mineral Densitometry T-Scores in Patients with Postmenopausal Osteoporosis Who Received Denosumab Treatment
Sağlam, G., & Alişar, D. Ç. (2021) · Turkish Journal of Osteoporosis · doi:10.4274/tod.galenos.2020.91249
Method for adjusting results of pharmacoeconomic studies from country to country using Bayesian statistics
Јаnkovic, S., Kostić, M., & Milovanovic, J. R. (2021) · Hospital Pharmacology - International Multidisciplinary Journal · doi:10.5937/hpimj2101998j
Osteoporosis in Postmenopausal Women with Breast Cancer
Lamond, J., & Shapiro, C. L. (2021) · OBM Geriatrics · doi:10.21926/obm.geriatr.2103173
Anti-resorptive Therapies
Clynes, M. A., & Dennison, E. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-78128-6_5
Antiresorptive Therapy for Osteoporosis
Murthi, S., & Liao, E. P. (2021) · Springer eBooks · doi:10.1007/978-3-030-83951-2_11
Current pharmacotherapy of osteoporosis and its future
Kukowka, A., Pluskota, M., Arciszewski, M., & Sroczyński, T. (2021) · Farmacja Polska · doi:10.32383/farmpol/145401
Effect of Desomumab on Improving ASD after Lumbar FusionPreprint
Qu, G., Zeng, Z., Luo, B., Zhao, L., Yang, J., Yang, Y., & Yuan, J. (2022) · Research Square · doi:10.21203/rs.3.rs-1493533/v1
The effect of kyphoplasty and vertebroplasty on denosumab discontinuation rebound fractures
Velitsikakis, P.-A., Kopanos, S., Giovanidis, G., Manta, A., & Zafeiris, C. (2023) · Journal of Research and Practice on the Musculoskeletal System · doi:10.22540/jrpms-07-033
Immune-based Therapies—What the Emergency Physician Needs to Know
Dubbs, S. B., Falat, C., & Rosenblatt, L. (2023) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2022.10.004
Awareness of medical doctor on medication-related osteonecrosis of the jaw in osteoporosis patients
Supanumpar, N., & Subbalekha, K. (2022) · doi:10.58837/chula.the.2022.267
Atypical Tibial Fracture Following Chronic Bisphosphonate Use: A Case Report and Review of the Literature
Sánchez-Fernández, H., Julbe, J. I. A., Gonzalez, J. A. R., Frontera, S. E., Ramírez, N., & Martinez, P. R. (2024) · Cureus · doi:10.7759/cureus.73165
Clinical Recommendations for the Perioperative Management of Biologic Medications for Nonrheumatologic Diseases in Total Joint Arthroplasty
Moya, A. R., Tehrany, P. M., Ghayyad, K., Yakkanti, R. R., & Pepper, A. M. (2025) · JBJS Reviews · doi:10.2106/jbjs.rvw.25.00004
EVALUATION OF THE EFFICACY OF SYSTEMICALLY APPLIED DENOSUMAB IN THE REPAIR OF BONE DEFECTS
PİRİNÇ, Ö., Hilal Türker, A. L. A. N., Gül, M., & Çetiner, Y. (2025) · İnönü Üniversitesi Sağlık Hizmetleri Meslek Yüksek Okulu Dergisi · doi:10.33715/inonusaglik.1568184
Osteoporosis Drugs: Old and New Drugs
Federica, B., & Radaelli, M. G. (2025) · Springer eBooks · doi:10.1007/978-3-032-01700-0_8
Platelet factor 4 induces bone loss by inhibiting the integrin α5-FAK-ERK pathwayPreprint
Liu, H., Zhang, Q., Gu, R., Li, W., Liu, Y., & Zhou, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-2028573/v1
Medicinal-chemistry-driven strategies for the synthesis of antiosteoclastogenic small molecules targeting RANKL and its downstream signaling pathways
Basit, A., & Wang, S. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118665
24-month real-world persistence and compliance of denosumab versus alendronate among postmenopausal women with osteoporosis in Australia, Taiwan, South Korea, Hong Kong, and Singapore
Lau, T. C., Chang, D., Chen, C., Huang, S., Lau, E. M. C., Law, S. W., Lee, Y., Tolman, C., Canals, L., Yeo, S., et al. (2026) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-026-01736-w
BindingDB Entry 50012161: Novel 2,7-Diazaspiro[4,4]nonane Derivatives to Inhibit Mouse and Human Osteoclast Activities and Prevent Bone Loss in Ovariectomized Mice without Affecting Bone Formation.
BindingDB (2022) · UC San Diego · doi:10.7270/q2v40zvj

Authors: Deeks, E. D.
Affiliations: Springer Nature (New Zealand) (NZ)
Corresponding author: Deeks, Emma D.
Venue: Drugs & Aging
Publisher: Springer Science and Business Media LLC
Published: 2018-02
Volume: 35
Issue: 2
Pages: 163-173
ISSN: 1170-229X (ISSN-L)
1179-1969
DOI: 10.1007/s40266-018-0525-7
OpenAlex: W2792392055
Cited by: 169
References: 55
Citations by year: 2026: 7 · 2025: 23 · 2024: 16 · 2023: 22 · 2022: 32 · 2021: 37 · 2020: 19 · 2019: 10 · 2018: 3
FWCI: 18.74
Type: journal article
Language: en
Update notices: correction (2018-03-09)
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Drugs & Aging (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords: denosumab, postmenopausal osteoporosis, RANKL, monoclonal antibodies, fracture risk, vertebral fractures, hip fracture, osteopenia, FREEDOM trial, drug discontinuation, adverse events, long-term treatment
MeSH terms: Denosumab, Aged, Clinical Trials as Topic, Female, Humans, Bone Density, Osteoporosis, Postmenopausal, Treatment Outcome, Bone Density Conservation Agents, Fractures, Bone, RANK Ligand

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Denosumab: A Review in Postmenopausal Osteoporosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks